Feast or famine in multiple sclerosis therapeutics

Despite this great progress, current multiple sclerosis treatments seem to predominantly benefit the inflammatory lesion activity that underlies relapsing multiple sclerosis, leaving the progressive aspects (ie, gradual disability worsening without clinical relapses) mostly unabated. Siponimod and o...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Lancet neurology 2020-03, Vol.19 (3), p.196-197
1. Verfasser:	Fox, Robert J
Format:	Artikel
Sprache:	eng
Schlagworte:	Alzheimer's disease Amiloride Atrophy Axon guidance Biomarkers Clinical trials Collaboration Drug development Drugs Famine Fluoxetine Inflammation Magnetic resonance imaging Multiple sclerosis Neuroprotection Patients Regulatory approval Systematic review
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!